Multi-Center Clinical Trial of Shenling Baizhu Granules for Preventing Low-Risk Colorectal Adenoma Recurrence

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

624

Participants

Timeline

Start Date

October 10, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Low-risk Colorectal Adenoma
Interventions
DRUG

Shenling Baizhu granules (TCM patent medicine)

Shenling Baizhu granules is a traditional Chinese medicine preparation in granular form. Participants in the experimental group will take 6 grams orally three times daily, before or with meals, for 6 months each year over a 2-year period. The granules contain multiple Chinese herbs including Ginseng, Poria, Atractylodes macrocephala, and other traditional ingredients. This formulation is standardized according to Chinese pharmacopoeia standards and is manufactured under GMP conditions. This intervention is being tested for its ability to prevent the recurrence of low-risk colorectal adenomas after endoscopic resection.

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER